Journey Medical (NASDAQ:DERM) Announces Quarterly Earnings Results

Journey Medical (NASDAQ:DERM) posted its earnings results on Wednesday. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.30, Zacks reports. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million.

Journey Medical Stock Up 1.3 %

Shares of Journey Medical stock traded up $0.07 on Friday, hitting $5.99. The company had a trading volume of 13,652 shares, compared to its average volume of 86,195. The stock has a 50-day moving average of $5.05 and a 200-day moving average of $5.16. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a twelve month low of $3.20 and a twelve month high of $6.89. The firm has a market capitalization of $125.21 million, a P/E ratio of -6.36 and a beta of 0.97.

Insider Buying and Selling

In other Journey Medical news, CEO Claude Maraoui sold 14,905 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.01, for a total transaction of $74,674.05. Following the completion of the transaction, the chief executive officer now owns 2,052,418 shares in the company, valued at approximately $10,282,614.18. This represents a 0.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 105,831 shares of company stock worth $536,622 over the last ninety days. Company insiders own 13.16% of the company’s stock.

Analyst Ratings Changes

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Journey Medical in a research note on Thursday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.67.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.